My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Marimastat (BB-2516)
    Marimastat (BB-2516)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V0739
    CAS #: 154039-60-8Purity ≥98%

    Description: Marimastat (formerly aslo known as BB2516; BB-2516; TA2516; TA-2516) is an orally bioactive and broad spectrum matrix metalloprotease (MMP) inhibitor with potential anticancer activity. It inhibits MMP-9/2/14/7 with IC50s of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Marimastat was studied in clinical trials but was terminated due to poor performance.

    References: Pharmacol Ther. 1997;75(1):69-75; Cancer Med. 2013 Aug;2(4):457-67. 

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)331.41
    CAS No.154039-60-8
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 54 mg/mL (162.9 mM)
    Water: <1 mg/mL
    Ethanol: 7 mg/mL (21.1 mM)
    Solubility (In vivo)50% DMSO+PBS: 30 mg/mL
    SynonymsBB 2516; TA-2516; Marimastat; BB-2516; BB2516; TA2516; TA 2516  

    Chemical Name: (2R,3S)-N1-((S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl)-N4,3-dihydroxy-2-isobutylsuccinamide


    InChi Code: InChI=1S/C9H20Cl2N2O5PS2/c10-2-4-13(5-3-11)19(14)12-9(1-6-18-19)20-7-8-21(15,16)17/h9,12,19H,1-8H2,(H,15,16,17)/q-1

    SMILES Code: O=C(N[[email protected]@H](C(C)(C)C)C(NC)=O)[[email protected]](CC(C)C)[[email protected]](O)C(NO)=O

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Marimastat (100 nM) significantly inhibits the expression of MMP14 in U251, U87, GBM39, and GBM43 tumor cells. Marimastat specifically inhibits the growth of glioma cells and has no effect on normal human astrocytes (NHA). Marimastat early down-regulates the expression of Notch target genes, such as Hes1 and Hes5.

    Kinase Assay: Recombinant human MMP2 is activated with 1 mM of 4-aminophenylmercuric acetate for 1 hour at 37°C. Rates of cleavage of 1 μM of the quenched fluorescent MMP substrate (7-methoxycoumarin-4-yl)acetyl-Pro-Leu-Gly-Leu-[3-(2,4-dinitrophenyl)-L-2,3-diaminoproprionyl]-Ala-Arg-NH2 are measured in 96-well fluorimetry plates at 37°C 100 mM Tris-HCl (pH 7.5), 100 mM NaCl, 10 mM CaCl2, 0.05% Brij 35 using a 320 nm excitation filter and a 405 nm emission filter in the presence of increasing inhibitor concentrations. Curve-fitting and IC50 calculations are done using GraphPad Prism 5.0 Software. 

    Cell Assay: In co-cultures of tumor spheroids derived from human glioma cell lines U251 and GaMG with RBA, marimastat strongly inhibits tumor invasion at concentrations of 10 μM. Marimastat (10 μM) significantly reduces cell proliferation by 54% and completely inhibits cell growth at 50 μM over 6 days. Also, marimastat (10 μM) reduces U251 spheroid growth by 65%.

    In VivoIn an orthotopic oral squamous cell carcinoma implantation model, marimastat (150 mg/kg/day, p.o.) administered by an osmotic pump significantly suppresses the cervical lymph node metastasis and activation of MMP-2, and has a significantly better survival than control group. Marimastat reduces MMP hyperactivity of polycystic human and rat cholangiocytes and blocks the cystic expansion of PCK cholangiocytes. Chronic treatment of 8-week-old PCK rats with marimastat inhibits hepatic cystogenesis and fibrosis.
    Animal modelOrthotopic oral squamous cell carcinoma implantation model
    Formulation & DosageDissolved in 50% DMSO (v/v) in PBS.; 150 mg/kg; oral gavage

    Clin Exp Metastasis. 2002;19(6):513-8; Gut. 2014 Oct;63(10):1658-67. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.



    Upregulation of MMP14 prolongs survival of glioma patients. Cancer Med. 2013 Aug;2(4):457-67. 


    Marimastat downregulates MMP14 expression and induces G2/M cell cycle arrest in gliomas. Cancer Med. 2013 Aug;2(4):457-67. 


    Genetic silencing of MMP14 results in glioma G2/M arrest. Cancer Med. 2013 Aug;2(4):457-67. 


    Temozolomide and radiation regulate MMP14 expression via microRNA374B in vitro and in vivo. Cancer Med. 2013 Aug;2(4):457-67. 


    Temozolomide (TMZ) and ionizing radiation (XRT) cooperate with inhibition of MMP14. Cancer Med. 2013 Aug;2(4):457-67. 


    MMP14 knockdown enhances antiglioma effect mediated by temozolomide (TMZ) and ionizing XRT in U251 glioma model. Cancer Med. 2013 Aug;2(4):457-67. 


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?